Transforming Brain Cancer Care
Every brain cancer patient is unique, and so is every brain tumor.
Neuro-oncology teams need new tools and insights to advance the state of care.
At Neosoma, our mission is to help clinicians improve outcomes by providing novel disease insights to physicians and clinical trials through innovative AI technology.
Brain Tumors Are Complex
Every Treatment Decision is Based on MRI Interpretation
Care is a multi-disciplinary process with significant limitations to treatment.
The Answers Are Hidden Within Every MRI
Critical data that is needed to improve treatment and outcomes exists inside every slice of each MRI.
Without Advanced AI Technology, These Insights will Never Be Accessed
Even the most expert clinicians are forced to use subjective judgement when assessing a brain tumor MRI.
Neosoma Uncovers Transformative Disease Insights
from Brain Tumor MRIs
Quantitative Imaging Biomarkers
Longitudinal Disease Assessment
Centralized Document Management
Virtual Tumor Board Sessions
Patient History and Timeline
A unified, clinican-validated software platform for the entire neuro-oncology team, combining tumor board workflow with multiple disease-specific AI-driven tumor analysis modules.
Seamless Integration; Deep Insights
Routinely-Acquired MRI Sequences
Clinical Management Platform
Neosoma Benefits Clinicians, Hospitals,
Patients, and Clinical Trials
Clinicians and Hospitals
We enable better clinical decisions, thereby raising the standard of care.
Hospitals drive increased patient volume and revenue, while reducing unnecessary costs.
Increased engagement with your physicians, better understanding of your disease and treatment protocol, and greater confidence in tumor change and response to treatment.
Research and Clinical Trials
Increase success and efficiency of clinical research and development through greater speed, accuracy, precision, and consistency of key endpoints, including tumor volumetrics.
See An Interactive Example Of A
High-Grade Glioma Segmentation
Use mouse wheel to scroll through slices.
In Clinicians' Own Words
“Clinicians commonly debate the results of brain MRIs and whether the brain tumor is stable, responding to treatment, or progressing. Neosoma HGG will give us the objectivity needed to make our decisions easier and more accurate.”
Isabelle M. Germano, MD, MBA, FACS
Professor of Neurosurgery and Director of the Comprehensive Brain Tumor Program at the Icahn School of Medicine at Mount Sinai